8 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 33929994 | Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia. | 2021 Oct 1 | 1 |
2 | 31299389 | Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment. | 2019 Sep | 1 |
3 | 29517106 | Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. | 2018 May | 1 |
4 | 24526731 | Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer. | 2014 Apr 15 | 1 |
5 | 23578175 | Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo. | 2013 Jul | 1 |
6 | 20371720 | ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. | 2010 Apr | 1 |
7 | 16937523 | Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects. | 2006 Aug 28 | 1 |
8 | 15367698 | ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. | 2004 Sep | 1 |